• Kymera Therapeutics to Present Preclinical Data on its First-in-Class IRAK4 Degraders Demonstrating Robust Inhibition of Inflammatory Responses and Superiority to IRAK4 Kinase Inhibitors

    • November 13, 2019
    • Posted By : admin
    • 0 Comment
    •   21 views

    Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough medicines for patients, today announced the company will present new preclinical data showing its first-in-class selective and potent oral IRAK4 degraders demonstrate broad and robust in vitro and in vivo inhibition of the toll-like receptor (TLR) and Interleukin-1 receptor (IL-1R) pathways underlying the pathogenesis of many inflammatory and autoimmune diseases. Data will be shared during an oral presentation (Abstract #1768) at the American College of Rheumatology Annual Meeting in Atlanta on Monday, November 11 at 3:30 PM EST.

    “IRAK4, a key component of the myddosome complex that mediates innate immune activation by TLRs and IL-1Rs, has both kinase and scaffolding functions, and both of which must be drugged to effectively inhibit proinflammatory cytokine and chemokine induction by those stimuli,” said Jared Gollob, MD, CMO, Kymera Therapeutics. “Our data showing broader and more potent inhibition of cytokine and chemokine induction by TLR agonists and IL-1b using IRAK4 degraders compared to IRAK4 kinase inhibitors support the further development of IRAK4 degraders for the treatment of dermatologic, rheumatic and gastrointestinal diseases caused by IL-1 family cytokines including IL-1a, IL-1b, IL-36, IL-18 and IL-33, as well as toll-like receptor activation.”

    “The TLR/IL-1R pathway has been extensively clinically validated by multiple biologics blocking individual IL-1 family cytokines with impact across a diverse set of autoinflammatory and autoimmune diseases,” said Nello Mainolfi, PhD, Founder, President & CSO, Kymera Therapeutics. “We are excited to advance this program into the clinic in 2020 and provide, with a single oral small molecule, a powerful and convenient solution to patients in need.”.

  21 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!